ALNYLAM PHARMACEUTICALS, INC. Payments to Acquire Available-for-sale Securities
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Payments to Acquire Available-for-sale Securities of $364.31 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-20.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2014-02-20
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2013-12-31 was $29.11M, a 64.27% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2013-09-30 was $60.77M, a 57.56% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2013-06-30 was $87.35M, a 124.59% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2013-03-31 was $187.08M, a 58.26% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2013 was $364.31M, a 31.46% increase from fiscal 2012.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2012 was $277.13M, a 5.45% decline from fiscal 2011.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2011 was $293.12M, a 24.93% decline from fiscal 2010.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2010 was $390.47M, a 18.88% decline from fiscal 2009.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2013-12-31 | $29.11M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $89.88M derived: sum of 2 quarters · filed 2014-02-20 | $177.23M derived: sum of 3 quarters · filed 2014-02-20 | $364.31M 10-K · filed 2014-02-20 |
| 2013-09-30 | $60.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $148.12M derived: sum of 2 quarters · filed 2013-11-07 | $335.20M 10-Q · filed 2013-11-07 | $416.65M derived: sum of 4 quarters · filed 2014-02-20 |
| 2013-06-30 | $87.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $274.43M 10-Q · filed 2013-08-09 | $355.88M derived: sum of 3 quarters · filed 2014-02-20 | $394.45M derived: sum of 4 quarters · filed 2014-02-20 |
| 2013-03-31 | $187.08M 10-Q · filed 2013-05-07 | $268.53M derived: sum of 2 quarters · filed 2014-02-20 | $307.10M derived: sum of 3 quarters · filed 2014-02-20 | $346.00M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-12-31 | $81.46M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $120.03M derived: sum of 2 quarters · filed 2014-02-20 | $158.92M derived: sum of 3 quarters · filed 2014-02-20 | $277.13M 10-K · filed 2014-02-20 |
| 2012-09-30 | $38.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $77.46M derived: sum of 2 quarters · filed 2013-11-07 | $195.67M 10-Q · filed 2013-11-07 | $270.97M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $38.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $157.10M 10-Q · filed 2013-08-09 | $232.40M derived: sum of 3 quarters · filed 2014-02-20 | $286.46M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | $118.21M 10-Q · filed 2013-05-07 | $193.50M derived: sum of 2 quarters · filed 2014-02-20 | $247.57M derived: sum of 3 quarters · filed 2014-02-20 | $369.54M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | $75.29M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $129.36M derived: sum of 2 quarters · filed 2014-02-20 | $251.32M derived: sum of 3 quarters · filed 2014-02-20 | $293.12M 10-K · filed 2014-02-20 |
| 2011-09-30 | $54.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $176.03M derived: sum of 2 quarters · filed 2012-11-05 | $217.82M 10-Q · filed 2012-11-05 | $320.80M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | $121.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $163.76M 10-Q · filed 2012-08-08 | $266.74M derived: sum of 3 quarters · filed 2013-02-19 | $372.16M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | $41.79M 10-Q · filed 2012-05-03 | $144.77M derived: sum of 2 quarters · filed 2013-02-19 | $250.19M derived: sum of 3 quarters · filed 2013-02-19 | $351.15M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | $102.98M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $208.40M derived: sum of 2 quarters · filed 2013-02-19 | $309.36M derived: sum of 3 quarters · filed 2013-02-19 | $390.47M 10-K · filed 2013-02-19 |
| 2010-09-30 | $105.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $206.38M derived: sum of 2 quarters · filed 2011-11-03 | $287.49M 10-Q · filed 2011-11-03 | $368.89M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-06-30 | $100.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03 | $182.08M 10-Q · filed 2011-08-03 | $263.47M derived: sum of 3 quarters · filed 2012-02-13 | $395.43M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-03-31 | $81.11M 10-Q · filed 2011-05-05 | $162.51M derived: sum of 2 quarters · filed 2012-02-13 | $294.46M derived: sum of 3 quarters · filed 2012-02-13 | |
| 2009-12-31 | $81.40M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13 | $213.35M derived: sum of 2 quarters · filed 2012-02-13 | $481.34M 10-K · filed 2012-02-13 | |
| 2009-09-30 | $131.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04 | $399.94M 10-Q · filed 2010-11-04 | ||
| 2009-06-30 | $267.99M 10-Q · filed 2010-08-05 | |||
| 2008-12-31 | $482.24M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |